Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-10-18 DOI:10.1016/j.vaccine.2025.127853

Chibueze Anosike , Iheomimichineke Mystery Ojiakor , Enyi Ifeoma Etiaba , Nkolika Pamela Uguru , Charles C. Ezenduka , Obinna Onwujekwe

{"title":"Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review","authors":"Chibueze Anosike , Iheomimichineke Mystery Ojiakor , Enyi Ifeoma Etiaba , Nkolika Pamela Uguru , Charles C. Ezenduka , Obinna Onwujekwe","doi":"10.1016/j.vaccine.2025.127853","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Despite the availability of malaria, measles, and meningitis vaccines in Africa, limited evidence on their cost-effectiveness and budget impact hinders informed policy decisions and sustainable allocation of scarce healthcare resources. We conducted a scoping review to synthesize available evidence on the cost-effectiveness and budget impact analysis of malaria, measles, and meningitis vaccines in Africa.</div></div><div><h3>Methods</h3><div>A literature search of PubMed, HINARI, and EBSCO Host databases was conducted to identify studies published in English between 2004 and 2024. The review was conducted and reported according to PRISMA-ScR guidelines. Eligible studies focused on the cost-effectiveness or budget impact of malaria, measles, and meningitis vaccines in African countries. Retrieved articles were subjected to title, abstract, and full text screening to determine if they met the eligibility criteria. Data was extracted from included papers, and incremental cost-effectiveness ratios were extracted or computed, when feasible, in 2024 US dollars.</div></div><div><h3>Results</h3><div>Forty-one (41) of the 885 retrieved articles were included in this review. The costing approach varied, with most studies valuing only direct costs. Transmission, mathematical, and Markov models were the predominant cost-effectiveness modelling methods. The cost per fully vaccinated child for malaria and measles vaccines ranged from US$4.20 to $52.35 and US$1.66 to $4.31, respectively. The costs per disability-adjusted years (DALYs) averted for malaria, measles, and meningitis vaccines ranged from US$22.63 to US$3314.01, US$1.60 to US$1239.35, and US$66.64 to US$4586.72, respectively. Most studies found that the three vaccines were more cost-effective than no intervention or other public health interventions. The budget impact of introducing the malaria vaccine in 41 African countries is about US$185 million.</div></div><div><h3>Conclusion</h3><div>There is limited evidence on the cost-effectiveness of the malaria, measles, and meningitis vaccines in Africa. The vaccines were largely cost-effective in Africa, although the budget impact of malaria vaccine is substantial.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"67 ","pages":"Article 127853"},"PeriodicalIF":4.5000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25011508","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Despite the availability of malaria, measles, and meningitis vaccines in Africa, limited evidence on their cost-effectiveness and budget impact hinders informed policy decisions and sustainable allocation of scarce healthcare resources. We conducted a scoping review to synthesize available evidence on the cost-effectiveness and budget impact analysis of malaria, measles, and meningitis vaccines in Africa.

Methods

A literature search of PubMed, HINARI, and EBSCO Host databases was conducted to identify studies published in English between 2004 and 2024. The review was conducted and reported according to PRISMA-ScR guidelines. Eligible studies focused on the cost-effectiveness or budget impact of malaria, measles, and meningitis vaccines in African countries. Retrieved articles were subjected to title, abstract, and full text screening to determine if they met the eligibility criteria. Data was extracted from included papers, and incremental cost-effectiveness ratios were extracted or computed, when feasible, in 2024 US dollars.

Results

Forty-one (41) of the 885 retrieved articles were included in this review. The costing approach varied, with most studies valuing only direct costs. Transmission, mathematical, and Markov models were the predominant cost-effectiveness modelling methods. The cost per fully vaccinated child for malaria and measles vaccines ranged from US$4.20 to $52.35 and US$1.66 to $4.31, respectively. The costs per disability-adjusted years (DALYs) averted for malaria, measles, and meningitis vaccines ranged from US$22.63 to US$3314.01, US$1.60 to US$1239.35, and US$66.64 to US$4586.72, respectively. Most studies found that the three vaccines were more cost-effective than no intervention or other public health interventions. The budget impact of introducing the malaria vaccine in 41 African countries is about US$185 million.

Conclusion

There is limited evidence on the cost-effectiveness of the malaria, measles, and meningitis vaccines in Africa. The vaccines were largely cost-effective in Africa, although the budget impact of malaria vaccine is substantial.

查看原文本刊更多论文

非洲疟疾、麻疹和脑膜炎疫苗的成本效益和预算影响：范围审查。

目标：尽管非洲有疟疾、麻疹和脑膜炎疫苗，但关于其成本效益和预算影响的证据有限，阻碍了知情的政策决定和稀缺的卫生保健资源的可持续分配。我们进行了范围审查，以综合有关非洲疟疾、麻疹和脑膜炎疫苗的成本效益和预算影响分析的现有证据。方法：检索PubMed、HINARI和EBSCO主机数据库的文献，确定2004年至2024年间发表的英文研究。审查是根据PRISMA-ScR指南进行和报告的。符合条件的研究侧重于非洲国家疟疾、麻疹和脑膜炎疫苗的成本效益或预算影响。对检索到的文章进行标题、摘要和全文筛选，以确定它们是否符合资格标准。从纳入的论文中提取数据，并在可行的情况下提取或计算增量成本-效果比，以2024美元计算。结果：885篇检索文章中的41篇被纳入本综述。成本计算方法各不相同，大多数研究只评估直接成本。传输模型、数学模型和马尔可夫模型是主要的成本效益建模方法。每位充分接种疟疾和麻疹疫苗的儿童的费用分别为4.20美元至52.35美元和1.66美元至4.31美元。疟疾、麻疹和脑膜炎疫苗避免的每个残疾调整年（DALYs）成本分别为22.63美元至3314.01美元、1.60美元至1239.35美元和66.64美元至4586.72美元。大多数研究发现，这三种疫苗比不干预或其他公共卫生干预更具成本效益。41个非洲国家引进疟疾疫苗的预算影响约为1.85亿美元。结论：关于非洲疟疾、麻疹和脑膜炎疫苗的成本效益的证据有限。这些疫苗在非洲基本上具有成本效益，尽管疟疾疫苗对预算的影响很大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.